INT15705

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 1986
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 46
Total Number 46
Disease Relevance 7.90
Pain Relevance 8.18

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
body 3
skeletal muscles 2
cortex 2
heart 2
myocardium 1
co (Mus musculus)
Pain Link Frequency Relevance Heat
depression 2 100.00 Very High Very High Very High
cINOD 16 99.96 Very High Very High Very High
tetrodotoxin 31 99.56 Very High Very High Very High
gABA 30 99.56 Very High Very High Very High
Analgesic 11 99.54 Very High Very High Very High
Hyperalgesia 15 99.20 Very High Very High Very High
Dorsal horn 2 98.62 Very High Very High Very High
Inflammation 34 97.96 Very High Very High Very High
antagonist 2 94.88 High High
Spinal cord 2 94.64 High High
Disease Link Frequency Relevance Heat
Depression 2 100.00 Very High Very High Very High
INFLAMMATION 33 99.68 Very High Very High Very High
Stress 407 99.36 Very High Very High Very High
Hyperalgesia 15 99.20 Very High Very High Very High
Hyperlipidemia 40 98.40 Very High Very High Very High
Nociception 2 96.28 Very High Very High Very High
Fever 1 94.32 High High
Generalized Anxiety Disorder 12 93.84 High High
Myalgia 20 92.72 High High
Congenital Anomalies 24 92.24 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The analgetic activity of inhibitors of 5-lipoxygenase (5-LO) and cyclooxygenase (CO) was investigated using rat Randall-Selitto (RS) hyperalgesia and mouse phenylbenzoquinone (PBQ)-induced abdominal constriction assays.
Negative_regulation (inhibitors) of CO associated with hyperalgesia
1) Confidence 0.42 Published 1991 Journal Agents Actions Suppl. Section Abstract Doc Link 1906235 Disease Relevance 0.25 Pain Relevance 0.25
SK&F 105809, a dual inhibitor of 5-LO/CO, significantly reduced hyperalgesia.
Negative_regulation (inhibitor) of CO associated with hyperalgesia
2) Confidence 0.31 Published 1991 Journal Agents Actions Suppl. Section Abstract Doc Link 1906235 Disease Relevance 0.28 Pain Relevance 0.35
These results suggest that dual inhibitors, and in particular, SK&F 105809 may be more efficient analgesic agents than selective CO inhibitors in clinical situations in which 5-LO products play a significant role.
Negative_regulation (inhibitors) of CO associated with analgesic
3) Confidence 0.31 Published 1991 Journal Agents Actions Suppl. Section Abstract Doc Link 1906235 Disease Relevance 0.23 Pain Relevance 0.33
Thus, improved analgetic activity appeared to result from inhibition of 5-LO and CO; whereas, in the RS assay, only CO inhibitors and SK&F 105809 were clearly effective.
Negative_regulation (inhibition) of CO
4) Confidence 0.31 Published 1991 Journal Agents Actions Suppl. Section Abstract Doc Link 1906235 Disease Relevance 0.26 Pain Relevance 0.34
In the PBQ assay, CO inhibitors were active, SK&F 105809 was nearly as potent as naproxen, and MK886 and phenidone were found to be active.
Negative_regulation (inhibitors) of CO
5) Confidence 0.31 Published 1991 Journal Agents Actions Suppl. Section Abstract Doc Link 1906235 Disease Relevance 0.28 Pain Relevance 0.35
When compared with the pattern of CO staining, levels of both CO and zinc were reduced in cortical territory innervated by the enucleated eye.
Negative_regulation (reduced) of CO in eye
6) Confidence 0.17 Published 2003 Journal Cereb. Cortex Section Abstract Doc Link 12967926 Disease Relevance 0 Pain Relevance 0.08
Thirty-one (62%) MMT patients had reduced carbon monoxide transfer factor (D(L)CO); 17 (34%) had elevated single breath alveolar volume (V(A)) and 43 (86%) had a reduced D(L)CO/V(A) ratio.
Negative_regulation (reduced) of CO
7) Confidence 0.07 Published 2004 Journal Addict Biol Section Abstract Doc Link 15511720 Disease Relevance 0.31 Pain Relevance 0.43
We postulated that the hydroxamic group might confer the ability to inhibit PO on conventional CO inhibitors.
Negative_regulation (inhibitors) of CO
8) Confidence 0.05 Published 1995 Journal J. Biol. Chem. Section Abstract Doc Link 7775455 Disease Relevance 0.07 Pain Relevance 0.22
Unlike many NSAIDs which are competitive inhibitors of CO, tepoxalin is a noncompetitive inhibitor of CO and its inhibitory effect on PO but not CO is reversed by excess heme.
Negative_regulation (reversed) of CO associated with cinod
9) Confidence 0.05 Published 1995 Journal J. Biol. Chem. Section Abstract Doc Link 7775455 Disease Relevance 0.09 Pain Relevance 0.27
While most nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit only the CO activity, we describe an inhibitor, tepoxalin, that inhibits both the CO (IC50 = 0.1 microM) and the PO (IC50 = 4 microM) activities.
Negative_regulation (inhibit) of CO associated with inflammation and cinod
10) Confidence 0.05 Published 1995 Journal J. Biol. Chem. Section Abstract Doc Link 7775455 Disease Relevance 0.10 Pain Relevance 0.29
Unlike many NSAIDs which are competitive inhibitors of CO, tepoxalin is a noncompetitive inhibitor of CO and its inhibitory effect on PO but not CO is reversed by excess heme.
Negative_regulation (inhibitor) of CO associated with cinod
11) Confidence 0.05 Published 1995 Journal J. Biol. Chem. Section Abstract Doc Link 7775455 Disease Relevance 0.09 Pain Relevance 0.28
The hydroxamic acid of tepoxalin is responsible for the PO inhibition since a carboxylic acid derivative of tepoxalin retains full CO but not PO inhibition.
Negative_regulation (inhibition) of CO
12) Confidence 0.05 Published 1995 Journal J. Biol. Chem. Section Abstract Doc Link 7775455 Disease Relevance 0.08 Pain Relevance 0.24
Unilateral retinal impulse blockage with tetrodotoxin (TTX) induces reversible shrinkage and decreased cytochrome oxidase (CO) activity in alternate rows of supragranular, CO-rich puffs in the adult macaque striate cortex (Wong-Riley & Carroll, 1984b: Carroll & Wong-Riley, 1987).
Negative_regulation (decreased) of CO in cortex associated with tetrodotoxin
13) Confidence 0.05 Published 1989 Journal Vis. Neurosci. Section Abstract Doc Link 2562110 Disease Relevance 0 Pain Relevance 0.27
Animals were subjected to 10 min of isocapnic dry gas hyperpnea or to quiet breathing of humidified gas and received as pretreatment either piroxicam, a cyclooxygenase (CO) inhibitor; A-63162, a 5-lipoxygenase (5-LO) inhibitor; BW-755c, a combined CO and 5-LO inhibitor; ICI-198,615, a leukotriene D4 receptor antagonist; or no drug.
Negative_regulation (inhibitor) of CO associated with antagonist
14) Confidence 0.04 Published 1993 Journal J. Appl. Physiol. Section Abstract Doc Link 8125904 Disease Relevance 0 Pain Relevance 0.14
In the present study, the levels of CoQ, in cytoplasm where NADPH-CoQ reductase are present, as well as in the mitochondria were measured (Table 1), and the results confirmed that statin administration reduces CoQ levels in mitochondria and cytoplasm among intracellular organelles.


Negative_regulation (reduces) of CoQ
15) Confidence 0.04 Published 2007 Journal Journal of Clinical Biochemistry and Nutrition Section Body Doc Link PMC2275764 Disease Relevance 0.18 Pain Relevance 0.09
The present study showed that statin administration decreased the body’s resistance to oxidative stress, and one of the factors may be decreased CoQ levels.
Negative_regulation (decreased) of CoQ in body associated with stress
16) Confidence 0.04 Published 2007 Journal Journal of Clinical Biochemistry and Nutrition Section Body Doc Link PMC2275764 Disease Relevance 0.35 Pain Relevance 0
Reduced and total CoQ (sum of oxidized and reduced CoQ) levels were measured by HPLC-electrochemical detector in accordance with the method of Okamoto et al. [44].
Negative_regulation (reduced) of CoQ
17) Confidence 0.04 Published 2007 Journal Journal of Clinical Biochemistry and Nutrition Section Body Doc Link PMC2275764 Disease Relevance 0 Pain Relevance 0
Furthermore, the CoQ level in the body has been reported to decrease after the age of 20 years, and this decrease is marked in tissues with high energy metabolism, such as the heart [50].
Negative_regulation (decrease) of CoQ in heart
18) Confidence 0.04 Published 2007 Journal Journal of Clinical Biochemistry and Nutrition Section Body Doc Link PMC2275764 Disease Relevance 0.09 Pain Relevance 0
Therefore, reduced CoQ levels may affect skeletal muscles and myocardium with active energy metabolism.
Negative_regulation (reduced) of CoQ in skeletal muscles
19) Confidence 0.04 Published 2007 Journal Journal of Clinical Biochemistry and Nutrition Section Body Doc Link PMC2275764 Disease Relevance 0.22 Pain Relevance 0.09
Simvastatin also reduced the activity of NADPH-CoQ reductase, a biological enzyme that converts oxidized CoQ to the corresponding reduced CoQ, while CoQ10 administration improved it.
Negative_regulation (reduced) of CoQ
20) Confidence 0.04 Published 2007 Journal Journal of Clinical Biochemistry and Nutrition Section Abstract Doc Link PMC2275764 Disease Relevance 0.20 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox